Foley Todd bought AKTS

January 12, 2026 · Form 4 insider transaction

Foley Todd bought 597,391 shares of Aktis Oncology, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
597,391
Price
N/A
Total value
N/A
InsiderFoley Todd
RoleDirector, 10% owner
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateJanuary 12, 2026
Filing dateJanuary 14, 2026
Shares owned after597,391
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC.; Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.; The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.; The shares are held as follows: 556,810 by BV 2018, 29,593 by BV 2018(B) and 10,988 by AM BV2018.

View the original Form 4 on SEC EDGAR
Foley Todd bought AKTS: January 12, 2026 | Insider Trading Screener